Q3 2026 Aytu Biopharma Inc Earnings Call Transcript

May 13, 2026 / 08:30 PM GMT

Release Date Price: $2.25 (-2.17%)

Transcript 10-Q8-K

Key Points

Positve

Aytu BioPharma Inc (AYTU) reported strong initial traction for Exua, with over 1,300 prescriptions written in Q3, indicating early adoption by physicians.
The company saw a 26% month-over-month growth in prescriptions from March to April, demonstrating increasing demand.
Exua's launch strategy is focused and disciplined, targeting high-prescribing psychiatry practices, which is yielding positive results.
The RxConnect program is effectively reducing barriers to access, with over 70% of prior authorizations being approved.
Positive patient feedback, including reports of life-changing experiences, suggests Exua is meeting a significant unmet need in major depressive disorder treatment.

Negative

Net revenue for the third quarter decreased by 33% year-over-year, primarily due to a strategic shift in focus and generic competition.
The ADHD portfolio experienced a significant decline in net revenue, dropping from $15.4 million to $9.1 million.
Gross profit margin decreased from 69% to 61% due to inventory write-downs and shifts in product focus.
The company reported a net loss of $5.6 million for the quarter, compared to a net income of $4 million in the prior-year period.
The pediatric portfolio also saw a decline in net revenue, impacted by payer mix and increased returns.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AYTU.OQ - Aytu Biopharma Inc
Q3 2026 Aytu Biopharma Inc Earnings Call
May 13, 2026 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day. Welcome to the A2 Biopharma Fiscal 2026 Q3 Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press *0 on your telephone keypad.

Please note, this conference is being recorded. I will now turn the conference over to your host, Robert Plume, Investor Relations. You may begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Great.

Thank you very much, and good afternoon, everyone. As the operator

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.